PT - JOURNAL ARTICLE AU - Van Egeren, Debra AU - Stoddard, Madison AU - White, Laura F. AU - Hochberg, Natasha S. AU - Rogers, Michael S. AU - Zetter, Bruce AU - Joseph-McCarthy, Diane AU - Chakravarty, Arijit TI - Vaccines alone cannot slow the evolution of SARS-CoV-2 AID - 10.1101/2022.10.04.22280696 DP - 2022 Jan 01 TA - medRxiv PG - 2022.10.04.22280696 4099 - http://medrxiv.org/content/early/2022/10/06/2022.10.04.22280696.short 4100 - http://medrxiv.org/content/early/2022/10/06/2022.10.04.22280696.full AB - The rapid emergence of immune-evading viral variants of SARS-CoV-2 calls into question the practicality of a vaccine-only public health strategy for managing the ongoing COVID-19 pandemic. It has been suggested that widespread vaccination is necessary to prevent the emergence of future immune-evading mutants. Here we examine that proposition using stochastic computational models of viral transmission and mutation. Specifically, we look at the likelihood of emergence of immune escape variants requiring multiple mutations, and the impact of vaccination on this process. Our results suggest that the transmission rate of intermediate SARS-CoV-2 mutants will impact the rate at which novel immune-evading variants will appear. While vaccination can lower the rate at which new variants appear, other interventions that reduce transmission can also have the same effect. Crucially, relying solely on widespread and repeated vaccination (vaccinating the entire population multiple times a year) is not sufficient to prevent the emergence of novel immune-evading strains if transmission rates remain high within the population. Thus, vaccines alone are incapable of slowing the pace of evolution of immune evasion, and vaccinal protection against severe and fatal outcomes for COVID-19 patients is therefore not assured.Competing Interest StatementA.C. and M.S. are employees of Fractal Therapeutics. A.C., M.S., D.V.E., and D.J.-M. are shareholders in Fractal Therapeutics.Funding StatementFractal Therapeutics provided salary support for author M.S., but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode required to reproduce the simulation results can be found on GitHub at https://github.com/dvanegeren/covid-var-emerge. https://github.com/dvanegeren/covid-var-emerge